MKI67 and breast carcinoma: These indicators depend heavily on primary tumour samples, are often expensive, strenuous and taking a lot of time and are usually limited their use in clinical practice.19 To a greater extent, it is complicated when some variable factors are taken into consideration such as ER status, PR status, Ki‐67 status, HER2 status of breast carcinoma or post‐operative adjuvant treatment.